We read with interest like Sipahi and colleagues' meta-analysis of angiotensin-receptor blockade and risk of cancer, and the accompanying comment by Steven Nissen in The Lancet Oncology. Both acknowledge the limitations of the analysis; particularly that it was based on a post-hoc analysis of an incomplete database. A major concern is that the trials included in Sipahi and co-workers investigation were not designed to explore cancer outcomes; we would therefore suggest that the results of the meta-analysis be interpreted cautiously.
展开▼
